Trials / Withdrawn
WithdrawnNCT01285505
Bioequivalence of a New and a Commercial Alprazolam Sublingual Formulation
Open-Label, Randomized, Single-Dose, 2-Way Crossover Bioequivalence Study Comparing A New Alprazolam Sublingual Tablet Formulation To An Alprazolam Sublingual Tablet
- Status
- Withdrawn
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
This study tests the hypothesis that the bioavailability of alprazolam from a new sublingual formulation is the same as that from an existing sublingual formulation.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | alprazolam commercial sublingual formulation | 0.5 mg tablet, single dose |
| DRUG | alprazolam test sublingual tablet | 0.5 mg tablet, single dose |
Timeline
- Start date
- 2011-04-01
- Primary completion
- 2011-06-01
- Completion
- 2011-06-01
- First posted
- 2011-01-28
- Last updated
- 2021-01-28
Source: ClinicalTrials.gov record NCT01285505. Inclusion in this directory is not an endorsement.